<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Mangosh TL</submitter><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><funding>National Institute of General Medical Sciences</funding><funding>NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>1235-1251</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8460604</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>81(15)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>To ensure replicative immortality in cancer, telomeres must be maintained through activation of telomere maintenance mechanisms (TMMs) that are dependent on telomerase or the alternative lengthening of telomeres (ALT) pathway. Although TMM pathways have traditionally been considered to be mutually exclusive, ALT hallmarks have been identified in cancers defined as being telomerase-positive, supporting TMM coexistence. In castration-resistant prostate cancer (CRPC), in vitro models were thought to be universally dependent on telomerase as the primary TMM; however, CRPC models with androgen receptor (AR) loss demonstrate ALT hallmarks with limited telomerase activity and require ALT-associated PML bodies (APBs) for sustained telomere maintenance. The TMM coexistence in AR-</pubmed_abstract><journal>The Prostate</journal><pubmed_title>SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines.</pubmed_title><pmcid>PMC8460604</pmcid><funding_grant_id>S10 OD016164</funding_grant_id><funding_grant_id>R01 GM133841</funding_grant_id><funding_grant_id>R01 CA240993</funding_grant_id><pubmed_authors>Grabowska MM</pubmed_authors><pubmed_authors>Mangosh TL</pubmed_authors><pubmed_authors>Taylor DJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines.</name><description>&lt;h4>Background&lt;/h4>To ensure replicative immortality in cancer, telomeres must be maintained through activation of telomere maintenance mechanisms (TMMs) that are dependent on telomerase or the alternative lengthening of telomeres (ALT) pathway. Although TMM pathways have traditionally been considered to be mutually exclusive, ALT hallmarks have been identified in cancers defined as being telomerase-positive, supporting TMM coexistence. In castration-resistant prostate cancer (CRPC), in vitro models were thought to be universally dependent on telomerase as the primary TMM; however, CRPC models with androgen receptor (AR) loss demonstrate ALT hallmarks with limited telomerase activity and require ALT-associated PML bodies (APBs) for sustained telomere maintenance. The TMM coexistence in AR-</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Nov</publication><modification>2026-05-31T16:01:28.922Z</modification><creation>2025-02-19T01:27:42.682Z</creation></dates><accession>S-EPMC8460604</accession><cross_references><pubmed>34492133</pubmed><doi>10.1002/pros.24225</doi></cross_references></HashMap>